MOSAR (Mastering hospital Antimicrobial Resistance and its spread into the community) is an Integrated Project of the EU’s 6 th Research Framework Programme. The MOSAR project is the first European-scale work devoted to the control and study of antimicrobial resistance in hospitals. MOSAR is coordinated by the Institut national de la santé e de la recherche médicale (INSERM, Christian Brun-Buisson, unit 657 "Pharmaco-epidemiology and assessment of the impact of health products on populations"), and has about 20 public and private laboratories, and more than 50 hospitals in Europe and Israel. The Kick off meeting has taken place in the Pasteur Institute in Paris on 12 and 13 February.
MOSAR will structure the network in a platform of services in order to establish industrial collaborations with the large private institutions of this field. All MOSAR members are highly involved in the fight against bacterial resistances. MOSAR is a 5-year integrated project, i.e., aiming to emphasize the scientific results. It has been financed with 10 million Euro by the European Commission, within the Seventh Framework Programme for Research And Development (FPRD).
MOSAR"s objectives are:
- To fine tune and to validate fast diagnostic tools permitting the earliest possible identification of multiresistant bacteria and of resistance mechanisms. To identify the risk of propagation of these multiresistant bacteria and to establish strategies of prevention and of more suitable treatments.
- To put into operation approximations to avoid the appearance and to contain spreading of these resistant bacteria in European hospitals, especially in the units more exposed to this problem (intensive care units, surgery and rehabilitation units).
- To achieve a better understanding on why some resistant bacteria are easily propagated in hospitals, and be able to identify the epidemic capacities of circulating bacteria.
- Finally, to conceive tools permitting a better adaptation of the strategies to control the transmission of these bacteria and the use of antibiotics.
Irradiated Bacterial Vaccine to Induce Broad Immune Response
UC Researchers have demonstrated that gamma-irradiated Listeria monocytogenes effectively immunizes mice against subsequent challenge with live Listeria. Unlike heat or formalin-killed bacteria, lethally gamma-irradiated bacteria provide protective immunity against both extracellular intracellular bacteria. The lethally irradiated bacterial vaccine appears to retain the immunogenicity and adjuvant effect of live Listeria but enjoys the safety and convenience of killed bacteria. This approach may serve as a basic vaccination platform for the generation of protective immunity and may be of particular interest for intracellular pathogens for which there is no current vaccine.
Practical and technical advantages of:
- Fast and inexpensive vaccine development, relative to standard anti-bacterial vaccines and recombinant subunit vaccines, which require identification of relevant microbial antigens
- Intrinsic bacterial adjuvant effect may obviate the need for adjuvant formulation
- Eliminating the need for dangerous, live organisms, which are often unsuitable for human vaccination
- Stability of irradiated, lyophilized vaccine stored at room temperature
- Efficacy against both intracellular and extracellular pathogens translate into medical advances, which include:
- Development of vaccines for disease in which there is currently no effective vaccine, e.g., those caused by intracellular bacteria
- Development of vaccines for diseases in which the bacterial pathogen is a bioterror agent, and as such, there is little or not time to develop vaccines using conventional methods and the
- Configuration of effective vaccines, which can include viral, bacterial, fungal, allergenic and tumor antigens.
Technology Transfer from the Weizmann Institute
Two non-toxic short peptides were conjugated to form a novel drug candidate. One of the peptides is a polymyxin-B or polymyxin-E analog (PMBN or PMEN, respectively) while the other is an immune cell chemotactic peptide (fMLF). The resultant new drug candidates (PMBN-fMLF or PMEN-fMLF) exhibit dual antimicrobial activities: it binds specifically to Gram-negative bacteria, thus enhancing penetration of antibiotics into the bacteria and at the same time it promotes bacterial killing by blood phagocytes.PMBN-fMLF was found to be active on a large number of clinical isolates. In vivo experiments in mice showed protection against Klebsiella pneumoniae following treatment with the drug. LD50 valude of PMBN-fMLF is ~3 fold loser than polymyxin-B. PMBN-fMLF exhibited potent in vitro and in vivo anti bacterial activity with a ~10 fold decrease in LD50, when compared to polymyxin-E.
- Rapid and effective destruction of bacteria via dual complementary killing mechanisms.
- Development of resistance is not anticipated owing to its novel mode of action.
BIORELIX, INC LICENSES UNIV. OF COLORADO RIBOSWITCH TECHNOLOGY
RNA technology will be used to develop treatment for antibiotic-resistant infections.
Boulder, CO) The University of Colorado recently executed an exclusive license with BioRelix, Inc. for riboswitch technology developed by Robert Batey in the Department of Chemistry and Biochemistry at CU-Boulder. BioRelix, founded in 2005 and based in New Haven, CT, was established to discover and develop novel and highly potent anti-infective compounds against pathogens resistant to currently available drugs.
Antibiotics have long been recognized as reliable drugs which have largely overcome the lethal and devastating effects of bacterial infections. However, all known classes of antibiotics are increasingly encountering wide-spread resistance by many prevalent bacterial pathogens; in fact, about 70 percent of bacteria that cause infections in hospitals are resistant to at least one of the drugs most commonly used to treat infections. Unless antibiotic resistance problems are detected as they emerge, and actions are taken to contain them, the world could be faced with previously treatable diseases that have again become untreatable, as in the days before antibiotics were developed.
Riboswitches are short stretches of messenger RNAs that bind small metabolites and control genes required for the survival of many disease-causing bacteria. Therefore, novel riboswitch technology may be used to defeat bacterial resistance to currently available antibiotics. BioRelix previously licensed jointly owned University of Colorado – Yale University riboswitch technology through a license with Yale, as well as another University of Colorado owned riboswitch technology. “We look forward to continuing a strong and mutually beneficial relationship with BioRelix,” declared Mary Tapolsky, Senior Licensing Associate with the University of Colorado’s Technology Transfer Office.